NICE draft guidance does not recommend Jardiance in new HF indication

8 February 2023

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued draft guidance, saying that it has not recommended the diabetes drug Jardiance (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction for use on the National Health Service (NHS).

Developed and marketed by family-owned German Boehringer Ingelheim and the USA’s Eli Lilly (NYSE: LLY), the Jardiance family of medicines generated first-half 2022 sales of $2.6 billion for the German firm, and $573.3 million in the third quarter for Lilly.

The companies noted that there are currently no clinically proven medications recommended by NICE for people with this condition, despite the Medicines and Healthcare products Regulatory Agency (MHRA) approval for empagliflozin to treat symptomatic chronic heart failure regardless of ejection fraction in June 2022. Reimbursement has already been granted for empagliflozin to treat patients with heart failure and mildly reduced or preserved ejection fraction (above 40%) in other countries outside the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK